Objective: As colorectal neuroendocrine tumors (NETs) are very rare, studies on this topic are limited. In this study, we presented the patients who were followed up in our clinic and described their clinicopathological features. Material and Methods: We retrospectively evaluated data collected from the patients with colorectal NETs admitted to our hospital from 2005 to 2023. The demographic characteristics of the patients, tumor characteristics, and treatments received were obtained from the files. Results: We included 25 patients in this study; 56% of the patients were male, and the median age of the patients was 55 (21-80) years. The most common locations of tumors were the proximal colon (52%) and rectum (44%). Among all tumors, 80% were Grade 1. Among the patients, 60% were T1 and 80% were N0. Moreover, 60% of patients were diagnosed in Stage 1. The median follow-up time was 5.4 years, and the five-year survival rate was 95.7%. Recurrence was observed in two patients. Among the three patients with metastases, one patient had metastasis in the liver, whereas the other two patients had metastasis in the liver, bone, and peritoneum. Additionally, a rectal NET patient had distant metastasis. Progression-free survival with a somatostatin analog was 43 months. The colonic NET patient with liver metastasis was administered a somatostatin analog, capecitabine-temozolomide, and radionuclide therapy, respectively. The colonic NET patient with distant metastasis was administered a somatostatin analog but died after five months. Conclusion: Colorectal NETs are rare. Most patients were diagnosed at an early stage, and surgical treatment was mostly sufficient.